评估间歇性与持续性林西替尼联合每周紫杉醇治疗复发性铂耐药卵巢上皮癌的2期研究
这项开放标签1/2期试验将152例难治性或铂耐药卵巢癌患者按1:1:1随机分配至间歇性林西替尼联合紫杉醇组、持续性林西替尼联合紫杉醇组或紫杉醇单药组。结果显示,两种林西替尼方案均未改善无进展生存期,间歇性林西替尼组不良事件发生率更高。
要点
- 间歇性林西替尼联合紫杉醇组中位无进展生存期2.8个月,持续性组4.2个月,紫杉醇单药组5.6个月。
- 两种林西替尼方案均未改善总缓解率、疾病控制率或总生存期。
- 间歇性林西替尼组不良事件发生率高于其他治疗组。
核心结论
- 在铂耐药或难治性卵巢癌患者中,间歇性或持续性林西替尼联合紫杉醇与紫杉醇单药相比未改善结局。
研究设计与样本
- 开放标签1/2期临床试验(NCT00889382),将难治性或铂耐药卵巢癌患者按1:1:1随机分配至A组(间歇性林西替尼600mg每日一次,每周第1-3天,联合紫杉醇80mg/m2第1、8、15天)、B组(持续性林西替尼150mg每日两次联合紫杉醇)或C组(紫杉醇单药)。
- 共152名女性被随机分配至治疗(A组n=51;B组n=51;C组n=50)。
- 主要终点为无进展生存期,次要终点包括总生存期、总缓解率、疾病控制率和安全性/耐受性。
主要发现
- 间歇性林西替尼联合紫杉醇组中位无进展生存期2.8个月(95%置信区间[CI]:2.5-4.4),持续性林西替尼联合紫杉醇组4.2个月(95%CI:2.8-5.1),紫杉醇单药组5.6个月(95%CI:3.2-6.9)。
- 与紫杉醇单药相比,两种林西替尼给药方案均未观察到总缓解率、疾病控制率或总生存期的改善。
- 间歇性林西替尼组不良事件发生率(包括所有级别和3/4级治疗相关不良事件,以及导致停药的治疗相关不良事件)高于其他治疗组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Linsitinib, an oral, dual inhibitor of insulin-like growth factor-1 receptor and insulin receptor, in combination with weekly paclitaxel, may improve clinical outcomes compared with paclitaxel alone in patients with refractory or platinum-resistant ovarian cancer. PATIENTS AND METHODS: This open-label phase 1/2 clinical trial (NCT00889382) randomized patients with refractory or platinum-resistant ovarian cancer (1:1:1) to receive either oral intermittent linsitinib (600mg once daily on Days 1-3 per week) combined with paclitaxel (80mg/m2 on Days 1, 8, and 15; Arm A) or continuous linsitinib (150mg twice daily) in combination with paclitaxel (Arm B), or paclitaxel alone (Arm C). Primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), overall response rate (ORR), disease control rate (DCR), and safety/tolerability. RESULTS: A total of 152 women were randomized to treatment (n=51 Arm A; n=51 Arm B, n=50 Arm C). In combination with paclitaxel, neither intermittent linsitinib (median PFS 2.8months; 95% confidence interval [CI]:2.5-4.4) nor continuous linsitinib (median PFS 4.2months; 95% CI:2.8-5.1) improved PFS over weekly paclitaxel alone (median PFS 5.6months; 95% CI:3.2-6.9). No improvement in ORR, DCR, or OS in either linsitinib dosing schedule was observed compared with paclitaxel alone. Adverse event (AE) rates, including all-grade and grade 3/4 treatment-related AEs, and treatment-related AEs leading to discontinuation, were higher among patients receiving intermittent linsitinib compared with the other treatment arms. CONCLUSION: Addition of intermittent or continuous linsitinib with paclitaxel did not improve outcomes in patients with platinum-resistant/refractory ovarian cancer compared with paclitaxel alone.
引用
- Oza A, Kaye S, Van Tornout J, et al. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. Gynecol Oncol. 2018. PMID: 29454514. doi:10.1016/j.ygyno.2018.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。